Optimizing the Management of Prostatitis: Levofloxacin and Silodosin—Strategies Aimed at Optimal Treatment for Prostatitis

29 March, 2017



A meeting on the treatment of prostatitis was held on May 5, 2013, in conjunction with the 108th American Urological Association (AUA) Annual Meeting in San Diego. Prostatitis and its related syndromes remain a frustrating urological problem, with an urgent need to clarify the best therapeutic strategies. Antibiotics and α-blockers provide important therapeutic options, with the fluoroquinolone levofloxacin a mainstay of treatment. This has been enhanced by the addition of the highly selective α-blocker silodosin, which is both effective and safe.

Professor Kurt G. Naber, Technical University of Munich, Germany, presented an excellent overview on the current state of treating bacterial prostatitis. Professor J. Curtis Nickel, Canada Research Chair in Urologic Pain and Inflammation, Queen’s University, Canada, then addressed the issue of how to manage patients with chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS).